13 reports of this reaction
1.8% of all TOLNAFTATE 1% reports
#9 most reported adverse reaction
RASH ERYTHEMATOUS is the #9 most commonly reported adverse reaction for TOLNAFTATE 1%, manufactured by Meijer Distribution Inc. There are 13 FDA adverse event reports linking TOLNAFTATE 1% to RASH ERYTHEMATOUS. This represents approximately 1.8% of all 724 adverse event reports for this drug.
Patients taking TOLNAFTATE 1% who experience rash erythematous should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH ERYTHEMATOUS is a less commonly reported adverse event for TOLNAFTATE 1%, but still significant enough to appear in the safety profile.
In addition to rash erythematous, the following adverse reactions have been reported for TOLNAFTATE 1%:
The following drugs have also been linked to rash erythematous in FDA adverse event reports:
RASH ERYTHEMATOUS has been reported as an adverse event in 13 FDA reports for TOLNAFTATE 1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH ERYTHEMATOUS accounts for approximately 1.8% of all adverse event reports for TOLNAFTATE 1%, making it a notable side effect.
If you experience rash erythematous while taking TOLNAFTATE 1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.